The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Alzheimer's disease failed clinical trials
Abstract
Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the Aβ plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Second-generation anti-amyloid antibody against soluble monomeric Aβ (solanezumab), insoluble monomeric Aβ (gantenezumab), and monoclonal antibody against multiple Aβ forms (crenezumab) failed to have efficacy in improving cognitive functions for mild and moderate AD in several clinical trials (Table 2, for example [36]).”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [36]
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
The Episodic Memory System: Neurocircuitry and Disorders
Dickerson, B. C., & Eichenbaum, H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.126 · Cited by 740
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Flagged first, then by citations
Research works printed but not linked: 1
- Schindowski, 2014, Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations, Degener. Neurol. Neuromuscul. Dis., 4, 121
Cited by
Sorted by citations
Items 101–127 of 127
Yang, Z., Zhang, M., Zhi, W., Lizhen, Hu, X., Zou, Y., & Wang, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031492 · Cited by 3
Kelliher, J. C., Engeland, C. G., Graham‐Engeland, J. E., Katz, M., Kessler, C., & Shearer, G. C. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101021 · Cited by 1
MINERVA: a public XAI-powered platform advancing multi-target discovery in Alzheimer’s disease
Gambacorta, N., Trisciuzzi, D., Mastrolorito, F., Leonetti, F., Altomare, C., de Candia, M., Catto, M., Amoroso, N., Ciriaco, F., & Nicolotti, O. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01253-y · Cited by 1
Is excess brain fluid an early marker of autism?
Guglielmi, G. (2023) · The Transmitter · doi:10.53053/ewgz1877 · Cited by 1
Ma, R., Li, Z., Guan, Y., Cheng, G., Song, Y., Dai, X., Wu, Z., & Chen, T. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150193 · Cited by 2
Fabian‐Fine, R., Roman, A. G., Winters, M. J., Lathram, K. J., Bennett, C. H., Kipingi, L. K., Brännare-Gran, S. M., Whitley, A. E., Paul, C. M., Altman, L. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.01.657219 · Cited by 1
Shared Genetic Architecture Between Kidney Function and Alzheimer Disease Across AncestriesPreprint
Yang, D., Yang, Y., Ray, N. R., Li, M., Benchek, P. H., Crawford, D. C., O’Toole, J. F., Sedor, J. R., Reitz, C., Lynn, A., et al. (2026) · medRxiv · doi:10.64898/2026.04.04.26350158 · Cited by 1
The cost and benefit of targeting amyloid plaques to treat alzheimer’s disease
Franklin Marisa, E., & Franklin, G. A. (2023) · Annals of Alzheimer s and Dementia Care · doi:10.17352/aadc.000027
MITOCHONDRIAL TRANSPLANTATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE (REVIEW)
Zhdanova, D. Y., & Chaplygina, A. V. (2023) · Problems of Biological Medical and Pharmaceutical Chemistry · doi:10.29296/25877313-2023-11-11
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936
Microvascular dysfunction in a murine model of Alzheimer’s disease using intravital microscopy
Sidsworth, D., Tregobov, N., Jamieson, C., Reutens-Hernandez, J., Yoon, J., Payne, G. W., & Sellers, S. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1482250
Cai, Q., Yang, Y., Wang, L., Zhou, Y., Liu, Y., Wu, P., Yang, F., Liu, Y., & Liu, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5350839
Cannabinoid Receptor 1: The Neural Gatekeeper of Health and Disease
Goyal, A., Kumari, A., Verma, A., Bhatiya, S., & Yadav, H. N. (2025) · Current Neurovascular Research · doi:10.2174/0115672026403497250910124233
Takeuchi, L. E., Lam, J., & Simmons, C. A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02152-3
A Comprehensive Review on Modelling Techniques in Drug Research and Development
Panda, K. C., Kumar, B. V. V. R., Jammula, S., Kumar, H. K. S., & Acharyya, S. (2026) · Applied Drug Research Clinical Trials and Regulatory Affairs · doi:10.2174/0126673371410546251201054257
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0
Therapeutic targeting of DNA repair pathway dysregulation in aging, cancer, and neurodegeneration
Kumar, V., Kashif, M., Singh, V., Rawat, R. S., Khan, A., Sarkar, G. C., & Majood, M. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2683686
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Qin, Y., Dong, X., Zhang, C., & Nao, J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158586
Beyond the Cochrane review: Re‐evaluating anti‐amyloid therapy in Alzheimer's disease
Bernath, M. M., Brosch, J. R., Saykin, A. J., Wilcock, D. M., Summanwar, D., & Willis, D. R. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71769
Reversing liver sinusoidal endothelial aging restores clearance of amyloid-beta and LDL
de Leve, S., Wang, X., Alavifard, H., Dara, L., & DeLeve, L. D. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113608 · Cited by 1
The role of acupuncture in the dendritic cell vaccine against Alzheimer's disease
Hong, Y., Shen, N., Yang, H., Ahmed, G., Regmi, D., Lin, X., Guo, N., Hearn, G., Sawmiller, D. R., & Cao, C. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261490135
Multitarget approaches in the treatment of Alzheimer’s disease: A new strategy in drug design
Pereira, M. V. S., Ribeiro, I. S., Aquino, W. C. P., Alfredo, L. H. M., da Paixao, Y. F., Despaigne, A. A. R., Moraes, M. N., & de Jesus, J. R. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.07.005
Discovery of novel pyridine-2-tetrazole derivatives as in vivo memory enhancement agents
Hung, N. V., Hoang, V.-H., Lê, T. B. L., Linh, V. N. H., Tien, L. Q., Linh, T. V. T., Bang, L. T. T., Nguyen, T. K., Pham, H. T. N., Minh, D. T., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110683
Metadata
- Authors
- Asher, S., & Priefer, R.
- Affiliations
- Massachusetts College of Pharmacy and Health Sciences (US)
- Corresponding author
- Priefer, Ronny
- ORCID
- Priefer, Ronny
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 306
- Pages
- 120861
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W4289732088
- Cited by
- 124
- References
- 61
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 34 · 2023: 29 · 2022: 8
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Life Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, clinical trial failure, amyloid plaques, tau tangles, anti-amyloid therapy, anti-tau therapy, cognitive function, neurodegeneration, therapeutic target
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Amyloid beta-Peptides, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
